Nina Oberbeck

Key facts

• Her employer announced a USD 65 million Series B in November 2025 led by Forbion with Eli Lilly joining; the release does not name prion disease.
• Listed as: Senior director of translational sciences; leads the prion programme at Gate Bioscience
• Leads Gate Bioscience's prion program as senior director of translational sciences.
• Presented at Prion 2024 and the 2023 national CJD conference in Melbourne.
• A 2025 CJD Foundation grant to her funds the Broad Vallabh Minikel lab to test whether a lead compound extends survival in a prion mouse model.
• The grant description reports 80 percent lower mouse brain PrP after one week of once-daily oral dosing.
• Gate states its prion therapeutic is in preclinical development and not yet ready for clinical trials.

Timeline

1. 2023National CJD conference presentation.
2. 2024Prion 2024 meeting presentation.
3. 2025Grant record published.